APA (7th ed.) Citation

Tintelnot, J., Stein, A., Batran, S. a., Ettrich, T. J., Götze, T., Grün, B., . . . Gökkurt, E. (2023). Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma: A phase II trial of the AIO study group (AIO STO 0321). Frontiers in oncology, 13, . https://doi.org/10.3389/fonc.2023.1272175

Chicago Style (17th ed.) Citation

Tintelnot, Joseph, et al. "Pembrolizumab and Trastuzumab in Combination with FLOT in the Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma: A Phase II Trial of the AIO Study Group (AIO STO 0321)." Frontiers in Oncology 13 (2023). https://doi.org/10.3389/fonc.2023.1272175.

MLA (9th ed.) Citation

Tintelnot, Joseph, et al. "Pembrolizumab and Trastuzumab in Combination with FLOT in the Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma: A Phase II Trial of the AIO Study Group (AIO STO 0321)." Frontiers in Oncology, vol. 13, 2023, https://doi.org/10.3389/fonc.2023.1272175.